EADV 2021 Highlights Podcast

 

In this episode, Medicom’s correspondent covers 6 presentations from the 30^th Congress of the European Academy of Dermatology and Venereology  (EADV 2021), held virtually from 29 September to 2 October 2021.

The topics discussed are:

1.     Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083

KHK4083/amlitelimab demonstrated great potential for the treatment of atopic dermatitis (AD). It not only induced significant reductions in Eczema Area and Severity Index (EASI) scores but also considerable maintenance of efficacy over 20 weeks in a recent phase 2 trial.

2.     Alopecia areata: Encouraging response rates with JAK3/TEC inhibition

Improvements in the Severity of Alopecia Tool (SALT) scores that translated to regrowth of hair in patients with alopecia areata (AA) were seen in patients treated with ritlecitinib at various dosages. Over a study course of 48 weeks, the agent showed no reason for safety concerns, as ritlecitinib was overall well tolerated.

3.      Topical tapinarof in psoriasis - high clearance rates and remittive effect

In PSOARING 3, extension treatment up to 52 weeks with tapinarof cream induced substantial rates of complete disease clearance in psoriatic patients. The responses were long-lasting even after the treatment was stopped.

4.     Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis

The JADE DARE head-to-head trial compared the efficacy of the JAK inhibitor abrocitinib with dupilumab in adult patients with moderate-to-severe atopic dermatitis (AD).  Abrocitinib showed a faster treatment effect and might be the right treatment option for patients with severe pruritus.

5.      Skin penetration of SARS-CoV-2: is it possible?

A French research group identified 3 key receptors for SARS-CoV-2 in several skin models: Moreover, they were able to modulate these receptors, indicating the possibility to develop a topical to protect virus transmission in patients with a compromised skin barrier.

6.      Superior EASI scores after switch from dupilumab to upadacitinib

Adults with moderate-to-severe atopic dermatitis demonstrated relevant outcome improvements after switching from dupilumab to upadacitinib. Within the open-label extension HEADS UP trial, no new safety signals were reported.

Enjoy listening!

Copyright ©2021 Medicom Medical Publishers



Posted on 19 October, 202118 November, 2021